GUIDELINES ON VALIDATION APPENDIX 4 ANALYTICAL …
Working document QAS/16.671 page 5 180 tests for impurities. Other analytical procedures include dissolution testing and determination of 181 particle size. 182 183 2.5 The results of analytical procedures should be accurate, legible, contemporaneous, 184 original, reliable and reproducible. All results should be archived for an appropriate period of
Download GUIDELINES ON VALIDATION APPENDIX 4 ANALYTICAL …
Information
Domain:
Source:
Link to this page:
Documents from same domain
INVESTING IN HEALTH FOR ECONOMIC …
www.who.int2 INVESTING IN HEALTH FOR ECONOMIC DEVELOPMENT Report by the Mexican Commission on Macroeconomics and health 3 The …
WHO GOOD PRACTICES FOR PHARMACEUTICAL …
www.who.intworking document qas/09.297/rev.2 page 2 schedule for the proposed adoption process of document qas/09.297/rev.2: who good practices for pharmaceutical microbiology laboratories
NORMES ET STANDARDS EN INFRASTRUCTURES …
www.who.intnormes et standards en infrastructures et equipements du centre de sante et de promotion sociale, du centre medical avec antenne chirurgicale et du …
Heterotrophic Plate Count Measurement in …
www.who.intWorld Health Organization Sustainable Development and Healthy Environments Heterotrophic Plate Count Measurement in Drinking Water Safety Management
Annex 3 WHO good manufacturing practices for ...
www.who.int96 Introduction The fi rst WHO draft text on good manufacturing practices (GMP) was prepared in 1967 by a group of consultants at the request of the Twentieth
Annex 5 WHO good distribution practices for …
www.who.int236 1. Introduction Distribution is an important activity in the integrated supply-chain management of pharmaceutical products. Various people and entities are
Annex 2 WHO good practices for pharmaceutical …
www.who.int71 Introduction and scope of document Pharmaceutical microbiology laboratories may be involved in: — sterility testing; — detection, isolation, enumeration and identifi cation of microorganisms
LABORATORY BIOSAFETY MANUAL - WHO
www.who.intinterim guidelines WHO/CDS/CSR/LYO/2003.4 LABORATORY BIOSAFETY MANUAL SECOND EDITION (REVISED) WORLD HEALTH ORGANIZATION Geneva 2003
Mycobacteriology Laboratory Manual - WHO
www.who.intMycobacteriology Laboratory Manual ii Edita Pimkina, Infectious Diseases and Tuberculosis Hospital Affi liate of Public institution …
Laboratory Guidelines for enumerating CD4 T …
www.who.intSEA-HLM-392 Distribution: Limited Laboratory Guidelines for enumerating CD4 T Lymphocytes in the context of HIV/AIDS Regional Office for South-East Asia
Related documents
ICH Topic Q 3 A Impurities Testing Guideline: Impurities ...
www.pharma.gally.chImpurities Testing Guideline: Impurities in New Drug Substances Step 5 NOTE FOR GUIDANCE ON IMPURITIES TESTING: IMPURITIES IN NEW DRUG SUBSTANCES (CPMP/ICH/142/95) APPROVAL BY CPMP May 1995 DATE FOR COMING INTO OPERATION (STUDIES COMMENCING AFTER) 1 November 1995. CPMP/ICH/142/95 1/11
IMPURITIES GUIDELINE FOR RESIDUAL S Q3C(R8) - ICH
database.ich.orgParent Guideline: Impurities: Guideline for Residual Solvents Q3C Approval by the Steering Committee under Step 2 and release for public consultation. ... equal to or below that recommended in this guideline, no testing of the drug product for residual solvents need be considered. If, however, the calculated level is above the recommended level ...
IMPURITIES GUIDELINE FOR RESIDUAL SOLVENTS Q3C(R6)
database.ich.orgICH HARMONISED GUIDELINE. IMPURITIES: GUIDELINE FOR RESIDUAL SOLVENTS. Q3C(R6) Final version . Adopted on 20 October 2016. This Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process.
Guideline on assessment and control of DNA reactive ...
www.ema.europa.euguideline is to provide a practical framework that is applicable to the identification, categorisation, qualification, and control of these mutagenic impurities , to limit potential carcinogenic risk associated with the exposure to potentially mutagenic impurities. This guideline is intended to complement VICH GL10 and VICH GL11.
ICH guideline M7 on assessment and control of DNA reactive ...
www.ema.europa.euM7 Q&As 2 18 PREFACE 19 20 Since the ICH M7 Guideline was finalized, worldwide experience with implementation of the recommendations for DNA reactive 21 (mutagenic) impurities has given rise to requests for clarification relating to the assessment and control of DNA reactive (mutagenic) 22 impurities. 23 24 This Question and Answer (Q&A) document is intended to …
STABILITY TESTING OF ACTIVE SUBSTANCES AND …
www.who.intWorking document QAS/06.179 page 2 REGIONAL GUIDELINE FOR THE WHO EASTERN MEDITERRANEAN REGION STABILITY TESTING OF ACTIVE SUBSTANCES AND PHARMACEUTICAL PRODUCTS DRAFT 2.0 19 April 2006 This guideline has been developed during the WHO EMRO Consultation on Regional